Targets › ALK
26 programs from 23 companies in 92 trials: 46 Phase 2, 27 Phase 1, 13 Phase 3, 6 Phase 4; Oncology; next expected readout Nov 2026.
Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue…. (UniProt, Q9UM73)
Open in Phaseline: the race on ALK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Ceritinib (LDK378) ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | ALK, EML4, NPM1 | Phase 4 | ALK Positive Malignancies; ALK-positive NSCLC; Neuroblastoma; ALK Positive … | Apr 2027 |
| Pfizer | crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 4 | NSCLC | Mar 2028 |
| Pfizer | Lorlatinib (PF-06463922) ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | ALK, EML4 | Phase 4 | Non-Small-Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Ganglioneuroblastoma; Non Small Cell Lung Cancer … | Dec 2028 |
| Pfizer | Lorlatanib ALK inhibitor | ALK | Phase 3 | Advanced Malignancies | Dec 2026 |
| IDEAYA Biosciences | Crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 3 | Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma … | Jan 2027 |
| Roche | Alectinib ALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; EML4-ALK inhibitor | ALK, RET, EML4 | Phase 3 | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Solid Tumors; ALK Fusion-positive Solid or CNS Tumors … | Jan 2027 |
| Roche | Entrectinib (RXDX-101) Neurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ALK tyrosine kinase receptor inhibitor | NTRK1, NTRK2, NTRK3, ROS1, ALK | Phase 3 | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Breast Cancer; Solid Tumors … | Jan 2027 |
| Nuvalent | Neladalkib (NVL-655) ALK inhibitor | ALK | Phase 3 | Non-small Cell Lung Cancer; Locally Advanced Solid Tumor | Dec 2027 |
| Shanghai Fosun Pharmaceutical Industrial Development | Foritinib Succinate (SAF-189s) ALK inhibitor | ALK | Phase 3 | Non-Small Cell Lung Cancer | Dec 2027 |
| Shenzhen TargetRx | TGRX-326 ALK inhibitor | ALK | Phase 3 | Non Small Cell Lung Cancer; Non-small Cell Lung Cancer | Nov 2028 |
| Xcovery Holdings | Ensartinib (X-396) ALK tyrosine kinase receptor inhibitor | ALK | Phase 3 | Non-small Cell Lung Cancer | – |
| Fundación GECP | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | Lung Cancer | Nov 2026 |
| Pingping Song | WX-0593 ALK and ROS1 tyrosine kinase inhibitor | ALK, ROS1 | Phase 2 | Non-Small Cell Lung Cancer(NSCLC) | Mar 2027 |
| CStone Pharmaceuticals | Lorlatinib ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | ALK, EML4 | Phase 2 | Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | May 2027 |
| University Health Network, Toronto | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | Pancreatic Ductal Carcinoma | Feb 2028 |
| Intergroupe Francophone de Cancerologie Thoracique | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | Non Small Cell Lung Cancer | Oct 2028 |
| Scott R. Plotkin, MD, PhD | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | Neurofibromatosis Type 2 | Dec 2029 |
| Groupe Francais De Pneumo-Cancerologie | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 2 | NSCLC | Oct 2030 |
| City of Hope Medical Center | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 1 | Locally Advanced Lung Non-Small Cell Carcinoma | Mar 2027 |
| Ascentage Pharma Group | APG-2449 Multi-targeted tyrosine kinase inhibitor; FAK, ALK, and ROS1 inhibitor | FAK, ALK, ROS1 | Phase 1 | Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid Cancer | May 2027 |
| Roberto Chiarle | Autologous hALK.CAR T cells Chimeric antigen receptor T cells targeting Anaplastic Lymphoma Kinase (ALK) | ALK | Phase 1 | Relapsed Neuroblastoma | Dec 2027 |
| M.D. Anderson Cancer Center | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 1 | Advanced Lung Carcinoma; Brain Metastasis | Jun 2028 |
| Shouyao Holdings (Beijing) Co. LTD | SY-12321 Fourth-generation ALK tyrosine kinase inhibitor | ALK | Phase 1 | ALK Positive Advanced Malignancies | Aug 2028 |
| Betta Pharmaceuticals | Ensartinib ALK tyrosine kinase receptor inhibitor | ALK | Phase 1 | Solid Advanced Tumor; Nonsmall Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Malignant Solid Neoplasm … | Feb 2029 |
| TRIANA Biomedicines | TRI-611 ALK molecular glue degrader | ALK | Phase 1 | ALK-positive NSCLC | May 2029 |
| Princess Maxima Center for Pediatric Oncology | Brigatinib ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ALK, EGFR | Phase 1 | Anaplastic Large Cell Lymphoma, ALK-Positive | Dec 2033 |
Non-small Cell Lung Cancer (8) Non-Small Cell Lung Cancer (6) Non Small Cell Lung Cancer (5) Advanced Lymphoma (4) Carcinoma, Non-Small-Cell Lung (4) Haematological Malignancy (4) Advanced Malignant Solid Neoplasm (3) Solid Tumors (3) Metastatic Colorectal Cancer (2) Lung Cancer (2) Brain Metastasis (2) ALK-positive NSCLC (2)
small molecule (19), mixed (4), other (1), protein or peptide (1)
Pfizer (3) Roche (2) IDEAYA Biosciences (1) Pingping Song (1) Roberto Chiarle (1) Shouyao Holdings (Beijing) Co. LTD (1) CStone Pharmaceuticals (1) Scott R. Plotkin, MD, PhD (1) Ascentage Pharma Group (1) Novartis (1) Shenzhen TargetRx (1) University Health Network, Toronto (1) Nuvalent (1) Fundación GECP (1) Groupe Francais De Pneumo-Cancerologie (1) City of Hope Medical Center (1) Shanghai Fosun Pharmaceutical Industrial Development (1) M.D. Anderson Cancer Center (1) TRIANA Biomedicines (1) Betta Pharmaceuticals (1)
EGFR (8) EML4 (6) ROS1 (5) NPM1 (3) MET (2) RET (1) NTRK1 (1) NTRK2 (1) NTRK3 (1) FAK (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.